A dual-functional in situ hydrogel for delivering vitamin E–based lipid nanoparticles to enhance cancer immunotherapy
Source abstract
Abstract
Conventional mRNA lipid nanoparticles often fail to elicit robust antitumor immunity due to their limited capacity to overcome the immunosuppressive tumor microenvironment (TME). Rational design of ionizable lipids with intrinsic bioactivity presents a promising strategy to enhance mRNA-based cancer immunotherapy. Here, we synthesized a bioactive vitamin E-based ionizable lipid to formulate lipid nanoparticles co-loaded with IL-12 mRNA and the IDO1 inhibitor NLG919 (N@VEBLNP), which were subsequently embedded into polyether F127-diacrylate hydrogel (NVF Gel). This hydrogel enables thermosensitive gelation for intratumoral injection and photocrosslinkable curing for postoperative site retention in the treatment of triple-negative breast cancer (TNBC). Specifically, NVF Gel exerted a dual immunomodulatory function: sustained release of N@VEBLNPs activated migratory cDC1s and augmented antigen presentation in tumor-draining lymph nodes, while concomitant release of NLG919 inhibited IDO1 expression, reduced regulatory T cells, and reprogrammed M2 macrophages toward the M1 phenotype. In 4T1 murine models, NVF Gel transformed the tumor environment into a more "immune-hot" state, effectively suppressed tumor growth and delayed postoperative recurrence. Collectively, NVF Gel provides a versatile platform for in situ cancer immunization and tumor microenvironment modulation.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (39)
Show source-provided references
1. A review of cancer immunotherapy: from the past, to the present, to the future10.3747/co.27.5223 ↗
2. New immune cell engagers for cancer immunotherapy10.1038/s41577-023-00982-7 ↗
3. Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders10.1038/s41573-022-00413-7 ↗
4. Small-molecule agents for cancer immunotherapy10.1016/j.apsb.2023.12.010 ↗
5. PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition10.3389/fimmu.2019.02022 ↗
6. Radiotherapy, immunity, and immune checkpoint inhibitors10.1016/S1470-2045(24)00075-5 ↗
7. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade10.1016/j.cell.2021.09.020 ↗
8. Bioactive polydopamine nanomedicines-assisted cancer immunotherapy
9. Vaccine-like nanomedicine for cancer immunotherapy10.1016/j.jconrel.2023.02.015 ↗
10. 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia10.1016/j.biomaterials.2015.07.020 ↗
11. Post-transcriptional control of cytokine production10.1038/ni1584 ↗
12. Local delivery of mRNA-encoding cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models10.1126/scitranslmed.abc7804 ↗
13. The potential role of N7-methylguanosine (m7G) in cancer10.1186/s13045-022-01285-5 ↗
14. RNA splicing factors as oncoproteins and tumour suppressors10.1038/nrc.2016.51 ↗
15. A lipid nanoparticle platform incorporating trehalose glycolipid for exceptional mRNA vaccine safety
16. Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering10.1021/acs.nanolett.9b04246 ↗
17. Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing10.1038/s41587-023-01679-x ↗
18. Targeting DTX2/UFD1-mediated FTO degradation to regulate antitumor immunity10.1073/pnas.2407910121 ↗
19. Immunostimulant citrus fruit-derived extracellular vesicle nanodrugs for malignant glioma immunochemotherapy10.1016/j.cej.2024.149463 ↗
20. The immunomodulatory effects of vitamins in cancer10.3389/fimmu.2024.1464329 ↗
21. Self-adjuvanting bacteria hydrogel for SHP1 checkpoint inhibition in tumor-draining lymph nodes to enhance cancer immunotherapy10.1002/adfm.202409736 ↗
22. Iterative screening of vitamin E-Based functional lipid nanoparticles for mRNA delivery10.1021/acsnano.5c01378 ↗
23. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy10.1016/j.ccell.2021.04.014 ↗
24. Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review10.1186/s12967-024-05104-y ↗
25. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy10.1093/annonc/mdw168 ↗
26. Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer10.1038/s41467-023-37806-0 ↗
27. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers10.1172/JCI96313 ↗
28. IDO inhibition facilitates antitumor immunity of Vγ9Vδ2 T cells in triple-negative breast cancer
29. Chitosan/calcium phosphates nanosheet as a vaccine carrier for effective cross-presentation of exogenous antigens10.1016/j.carbpol.2019.115172 ↗
30. Generation of an inflammatory niche in a hydrogel depot through recruitment of key immune cells improves efficacy of mRNA vaccines10.1126/sciadv.adr2631 ↗
31. An mRNA lipid nanoparticle-incorporated nanofiber-hydrogel composite for cancer immunotherapy10.1038/s41467-025-61299-8 ↗
32. In-situ trichosanthin-IL2/pectin dynamic hydrogel activates dendritic cells and reverses T cell exhaustion for post-operative cancer therapy10.1016/j.cej.2025.159426 ↗
33. miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy10.1007/s00262-020-02507-w ↗
34. A cell-free kinetic analysis of ionizable lipid hydrolysis10.1021/acs.analchem.4c02399 ↗
35. Silicon ether ionizable lipids enable potent mRNA lipid nanoparticles with rapid tissue clearance10.1021/acsnano.3c09028 ↗
36. Macrophage polarization states in the tumor microenvironment10.3390/ijms22136995 ↗
37. For and against tumor microenvironment: nanoparticle-based strategies for active cancer therapy
38. Myeloid derived suppressor cells and innate immune system interaction in tumor microenvironment10.1016/j.lfs.2022.120755 ↗
39. Therapeutic targeting of tumour myeloid cells10.1038/s41568-022-00546-2 ↗